Traws Pharma, Inc.
TRAW · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0% | 0% | 0% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 94.7% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -73,677.4% | -8,974.3% | -8,678.3% | -7,292.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -24,192% | -8,384.1% | -8,391.2% | -7,151.8% |
| EPS Diluted | -35.21 | -22.569 | -22.675 | -24.006 |
| % Growth | -56% | 0.5% | 5.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |